[Bleomycin in gynecologic squamous cell carcinoma. (Preliminary report on therapeutic and adverse effects)].
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D007272:Injections, Intralymphatic; D008207:Lymphatic Metastasis / Q000188:drug therapy; D008220:Lymphography; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011014:Pneumonia / Q000139:chemically induced; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000000981:diagnostic imaging; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014846:Vulvar Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin
Bleomycin bei gynäkologischen POlattenepithelkarzinomen. (Vorläufige Mitteilung über therapeutische Effekte und Nebenwirkungen.